Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' DEFICIT (Details 4)

v3.4.0.3
STOCKHOLDERS' DEFICIT (Details 4) - $ / shares
6 Months Ended
Mar. 31, 2016
Sep. 30, 2015
Exercise Price $ 0.75 $ 0.75
Warrant [Member]    
Number of Shares 87,946,522  
Weighted Average Exercise Price $ 0.05  
Warrant [Member] | $0.04718 [Member]    
Exercise Price $ 0.04718  
Number of Shares 38,152  
Expiration Date 2018-03  
Weighted Average Exercise Price $ 0.04718  
Warrant [Member] | $0.05 [Member]    
Exercise Price $ 0.05  
Number of Shares [1] 27,200,000  
Weighted Average Exercise Price $ 0.05  
Expiration Date Dec. 31, 2020  
Warrant [Member] | $0.05 [Member]    
Exercise Price $ 0.05  
Number of Shares [2] 60,000,000  
Weighted Average Exercise Price $ 0.05  
Expiration Date Dec. 31, 2020  
Warrant [Member] | $0.25 [Member]    
Exercise Price $ 0.25  
Number of Shares 332,200  
Weighted Average Exercise Price $ 0.25  
Warrant [Member] | $0.25 [Member] | Maximum [Member]    
Expiration Date 2017-07  
Warrant [Member] | $0.25 [Member] | Minimum [Member]    
Expiration Date 2016-04  
Warrant [Member] | $0.275 [Member]    
Exercise Price $ 0.275  
Number of Shares 324,000  
Weighted Average Exercise Price $ 0.275  
Warrant [Member] | $0.275 [Member] | Maximum [Member]    
Expiration Date 2019-03  
Warrant [Member] | $0.275 [Member] | Minimum [Member]    
Expiration Date 2018-06  
Warrant [Member] | $1.00 [Member]    
Exercise Price $ 1  
Number of Shares 32,168  
Weighted Average Exercise Price $ 1  
Warrant [Member] | $1.00 [Member] | Maximum [Member]    
Expiration Date 2017-01  
Warrant [Member] | $1.00 [Member] | Minimum [Member]    
Expiration Date 2015-10  
Warrant [Member] | $7.50 [Member]    
Exercise Price $ 7.5  
Number of Shares 3,334  
Expiration Date 2016-05  
Weighted Average Exercise Price $ 7.5  
Warrant [Member] | $9.00 [Member]    
Exercise Price $ 9  
Number of Shares 16,668  
Expiration Date 2017-07  
Weighted Average Exercise Price $ 9  
[1] (1) On December 23, 2015, the Company entered into a Second Amended Note and Warrant Purchase Agreement pursuant to which on December 23 and December 28, 2015, the Company issued December 2015 Notes to the two purchasers for an aggregate principal amount of $1,000,000 and issued a Note Warrant to each holder of December 2015 Notes to purchase the Company's Common Stock, in an amount equal to 100% of the shares underlying their December 2015 Note. Each Note Warrant is exercisable, in whole or in part, during the period beginning on the date of its issuance, and ending on the earlier of (i) December 31, 2020 and (ii) the date that is forty-five (45) days following the date on which the daily closing price of shares of the Company's Common Stock quoted on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Company's Common Stock is traded or listed) exceeds $0.25 for at least ten (10) consecutive trading days. In connection therewith, the Company will promptly notify the Note Warrant holders in the event that the daily closing price of the Company's shares of Common Stock so exceeds $0.25 for at least ten (10) consecutive trading days. Both December 2015 Notes and Note Warrants were purchased by affiliates of the Company, or an entity under such affiliate's control, as follows: (i) on December 23, 2015, John Pappajohn, a member of the board of directors of the Company, purchased a December 2015 Note for $250,000 and was issued a Note Warrant to purchase 5,000,000 shares of Common Stock; and (ii) on December 28, 2015, RSJ PE, of which, Michal Votruba, a member of the board of directors of the Company, is the Director for Life Sciences for the RSJ/Gradus Fund, purchased a December 2015 Note for $750,000 and was issued a Note Warrant to purchase 15,000,000 shares of Common Stock.
[2] (2) On December 23, 2015, in consideration for the agreement to extend the maturity date of the Notes, the Company issued to holders of all Notes outstanding prior to the date of the Second Amended Note & Warrant Agreement, Extension Warrants to purchase an aggregate of 60,000,000 shares of Common Stock. Each such holder was issued an Extension Warrant to purchase Common Stock in an amount equal to 100% of the shares underlying each such holder's previously outstanding Notes. 11 million Extension Warrants were issued to 10 accredited investors and 49 million Extension Warrants were issued to Directors and Affiliates; for further detail refer to Note 7. Related Party Transactions.